Semax and Selank: A Primer on Russia's Two Most Studied Cognitive Peptides

Most of the peptide discussion in Western sports medicine and longevity circles centers on BPC-157, TB-500, and GH secretagogues — compounds with mechanisms rooted in tissue repair and metabolic optimization. There's a parallel category that gets considerably less attention: the Russian neurological peptides, developed over decades of serious Soviet and post-Soviet neuropharmacology research.

Semax and Selank are the two most researched and most used of these. They were developed at the same institution — the Institute of Molecular Genetics of the Russian Academy of Sciences — and have both been approved as prescription medications in Russia. They're also often discussed together as a potential combination. But they're distinct compounds with distinct mechanisms, distinct research, and distinct practical profiles, and the most common mistake is treating them as interchangeable cognitive enhancers when they really aren't.

This post is a primer: what each compound is, how it works, what the evidence shows.

Background: Why These Compounds Deserve Attention

Before getting into the specifics, the broader context matters. Soviet and Russian neuropharmacology has a different research tradition than Western pharmaceutical development — more focused on naturally derived regulatory peptides, with a deeper clinical observation database in certain neurological conditions, and with a provenance question that should be named plainly: the majority of Semax and Selank research comes from Russian institutions, which creates the same independent replication problem we've discussed for BPC-157 and Pinealon, only more acutely.

What's different here compared to Pinealon: both Semax and Selank have regulatory approval in Russia for specific indications — Semax for ischemic stroke and cognitive impairment, Selank for generalized anxiety disorder. That's a higher bar than purely experimental compounds. Russian drug approval is not equivalent to FDA approval, but it does mean these compounds have passed through some clinical evaluation process and are available as formulated, quality-controlled pharmaceutical preparations in their country of origin. That's a meaningful distinction from gray-market research peptides assembled in overseas labs.

There's also a notable regulatory development worth mentioning upfront: Semax is one of seven peptides scheduled for FDA Pharmacy Compounding Advisory Committee review on July 24, 2026, being evaluated for cerebral ischemia, migraine, and trigeminal neuralgia. This is a live regulatory process, not a historical footnote — the Western clinical evaluation of Semax is beginning.

Semax: The Cognitive Enhancement and Neuroprotection Compound

What It Is

Semax was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s and has been used as a prescription medication in Russia since 2011 for stroke recovery, cognitive impairment, and neurodegenerative conditions. The peptide sequence is Met-Glu-His-Phe-Pro-Gly-Pro, with a modified C-terminal proline that increases enzymatic stability and extends its half-life compared to the native ACTH fragment.

The design is intentional: Semax retains ACTH's neurotrophic properties while eliminating its hormonal effects. Full-length ACTH raises cortisol by stimulating the adrenal cortex. Semax was engineered to lack this activity — it doesn't activate MC2R (the adrenal ACTH receptor) but retains affinity for MC4R and MC3R in the central nervous system, where melanocortin signaling modulates neuroplasticity and neuroprotection. This design allows brain-supportive effects without adrenal stimulation or the cortisol consequences that would make long-term use problematic.

The Primary Mechanism: BDNF Upregulation

The strongest mechanistic evidence for Semax's neuroprotective action comes from its effects on brain-derived neurotrophic factor (BDNF), a protein that supports neuron survival, growth, and synaptic plasticity.

The landmark data: a single intranasal dose of 50 μg/kg in rodents increased BDNF mRNA expression 3-fold in the hippocampus, with a concurrent 1.6-fold increase in TrkB receptor phosphorylation — the receptor that BDNF signals through. Consistent results appear across multiple rodent behavioral paradigms: Semax enhances conditioned avoidance reactions and learning-dependent behaviors, memory consolidation improves, and attention sharpens. These cognitive gains correlate with measured BDNF/TrkB increases in the hippocampus — mechanism and behavioral outcome lining up.

BDNF matters here because its decline is one of the most consistent neurobiological correlates of cognitive aging. It's also dysregulated in depression, and is the downstream target of antidepressants and exercise — both of which raise BDNF. Semax appears to directly upregulate it through a different upstream mechanism.

Additional Mechanisms

Unlike most experimental neuroprotective agents that target a single pathway, Semax appears to work across multiple systems simultaneously — neurotrophic factor production, immune modulation, vascular repair, and neurotransmitter regulation.

Dopaminergic and serotonergic activation have been documented within 30 minutes of intranasal administration in rats — which likely contributes to the reported stimulant-adjacent cognitive effects (alertness, focus, reduced mental fatigue). The Pro-Gly-Pro C-terminal extension is itself pharmacologically active, independently activating neurotrophin transcription in ischemic brain tissue — it's a second functional component within the molecule, not just a stability modification.

Antioxidant neuroprotective properties include upregulation of endogenous antioxidant enzymes (SOD, catalase, GPx) and reduction of lipid peroxidation — relevant to the oxidative stress component of both aging and stroke injury. A 2024 study found antidepressant-like and antistress effects in multiple chronic unpredictable stress models in rats.

The Stroke Evidence: The Strongest Clinical Signal

For ischemic stroke specifically, Semax has the most credible human evidence in this compound category. Russian clinical studies documented reductions in ischemic infarct volume in animal models, and clinical application in stroke recovery is Semax's approved indication. A 2020 ischemia-reperfusion study found Semax compensated for mRNA expression disruption during ischemia-reperfusion, suppressed inflammatory and cell-death processes, and activated recovery pathways at both transcriptome and protein levels.

The honest caveat: these are Russian clinical studies, not large international RCTs. The evidence is consistent and mechanistically coherent, but the independent replication standard that Western regulators would require for approval isn't yet met — hence the July 2026 FDA advisory committee review being meaningful.

What Semax Feels Like in Practice

The experiential profile reported in Russian clinical practice and the nootropic community: stimulant-adjacent alertness without the cardiovascular effects of caffeine or amphetamine, improved focus and mental endurance during cognitively demanding work, faster information processing. It is not sedating. Some users report tolerance development with continuous daily use — cycling protocols (several weeks on, one week off) are common in practice.

The most commonly reported adverse effect: mild nasal irritation with intranasal use, and in about 10% of cases, nasal cavity discoloration. Mild increases in blood glucose have been reported in diabetic patients at around 7.4%. These are the safety signals from the Russian prescription context — the longest-duration safety observation available.

Selank: The Anxiolytic Cognitive Peptide

What It Is

Selank is a synthetic analog of the immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg), with an added Gly-Pro sequence that improves metabolic stability. It was developed at the same institute and has been studied extensively as an anxiolytic. Selank received regulatory approval in Russia as a prescription anxiolytic and nootropic medication.

Tuftsin is a naturally occurring tetrapeptide found in the heavy chain of immunoglobulin G, involved in immune regulation. Selank uses the tuftsin core but extends it with a Gly-Pro tripeptide that dramatically improves metabolic stability — the parent tuftsin molecule is rapidly degraded in plasma, while Selank's modification allows it to maintain activity long enough to produce CNS effects. This is the same design logic as Semax's Pro-Gly-Pro extension.

The Primary Mechanism: GABAergic Modulation Without Benzodiazepine Problems

Research has identified several mechanisms through which Selank appears to work. The most studied involves allosteric modulation of the GABAergic system, affecting genes involved in GABA neurotransmission without directly binding to receptors.

This distinction is clinically important. Benzodiazepines (diazepam, alprazolam) also work through GABAergic modulation — they bind directly to GABA-A receptors and produce their sedation, anxiolysis, and addiction potential through that direct agonism. Selank interacts with the GABAergic system through allosteric modulation and gene expression changes in GABA-related genes, producing anxiolytic effects via a different mechanism. The consequence: anxiolysis without sedation, without cognitive impairment, and without the tolerance and dependence profile that makes benzodiazepines problematic for long-term use.

A 2016 Frontiers in Pharmacology study confirmed significant changes in gene expression following Selank administration, particularly in genes associated with mood regulation and anxiety — providing molecular-level evidence that the GABAergic interaction produces lasting neurochemical shifts rather than just acute receptor modulation.

The Enkephalin Connection

The relationship between Selank and the enkephalin system represents an area of ongoing scientific investigation. Enkephalins are endogenous opioid peptides involved in pain regulation and stress response. Selank appears to slow the metabolic degradation of enkephalins, effectively extending their activity — providing an indirect modulation of the opioid system that contributes to both anxiolytic and mild analgesic effects without direct opioid receptor agonism.

The human evidence connecting this to clinical outcomes: the clinical-biological study of 62 GAD patients revealed that patients with generalized anxiety disorder and neurasthenia had decreased levels of enkephalin degradation speed, correlated with disease duration, severity of anxiety and asthenic symptoms, and autonomic disorders. Selank's normalization of enkephalin metabolism appears to be part of how it addresses this specific patient profile.

The Human Clinical Evidence

Selank has the strongest human clinical data of any compound discussed in this post — a genuine comparative clinical study rather than a case series.

One notable study examined 62 patients with generalized anxiety disorder, comparing Selank to the benzodiazepine medazepam. The anxiolytic effects of both compounds were similar — but with an important difference in the profile. The Selank group also showed antiasthenic (fatigue-reducing) and psychostimulant effects that the benzodiazepine group did not. Medazepam produced anxiolysis plus sedation; Selank produced anxiolysis plus cognitive clarity. That asymmetry is the clinical argument for Selank as an alternative for patients where benzodiazepine sedation and dependence risk are concerns.

This is still a single study from Russian institutional research, and 62 patients isn't a large trial by international standards. But a head-to-head comparison with an established anxiolytic, showing comparable efficacy with a more favorable side effect profile, is a meaningful piece of clinical evidence — considerably more than most peptide discussions can point to.

What Selank Feels Like in Practice

The reported experiential profile is the inverse of Semax in key respects: calming rather than stimulating, anxiety-reducing rather than focus-sharpening, and mildly sedating at higher doses. Some users describe it as producing "calm clarity" — reduced anxiety without the cognitive blunting that benzodiazepines produce. The immunomodulatory properties from its tuftsin heritage mean it also appears to have cytokine-regulatory effects — Selank modulates IL-6 and interferon expression, which is consistent with its tuftsin-derived origin and may be relevant in contexts where neuroinflammation contributes to anxiety.

Comparing the Two: Different Tools, Different Problems

The most useful framing: Semax is a well-studied synthetic peptide with consistent preclinical evidence for BDNF upregulation, dopaminergic and serotonergic activation, and neuroprotection in stroke models. Selank's anxiolytic data is the strongest evidence available in its class.

They address different bottlenecks to cognitive performance:

Semax is the cognitive activation compound — it sharpens, energizes, and neuroprotects. It's most relevant when the problem is suboptimal neurotrophin signaling, cognitive fatigue, or neurodegenerative risk. It has a mild stimulant character.

Selank is the anxiety-modulation compound — it calms, stabilizes, and reduces the anxious activation that impairs cognitive performance. It's most relevant when anxiety is the limiting variable, not neurotrophin support.

They're commonly combined for exactly this reason: Semax's mild stimulant profile can produce anxiety or edginess in susceptible individuals, and Selank smooths that edge. The cognitive activation plus anxiety modulation combination is the most popular use pattern in both Russian clinical practice and the Western nootropic community.

How They Compare to Other Cognitive Peptides

In the context of this newsletter's ongoing coverage of cognitive compounds: Semax and Selank have a meaningfully stronger evidence base than Pinealon (the EDR peptide) discussed in an earlier post. The key differences:

• Both have Russian regulatory approval for specific indications, not just research status
• Selank has a genuine comparative clinical trial against an established drug
• Semax has decades of clinical observation data from its approved prescription use in Russia
• Semax is currently in active Western regulatory evaluation (July 2026 FDA advisory committee)

The provenance concern — research concentrated in Russian institutions with limited Western replication — applies here as it does to Pinealon. But the depth of the Russian evidence base and the regulatory approval status mean these compounds are further along the development curve.

Routes of Administration and the Intranasal Advantage

Both compounds are typically administered intranasally — as nasal spray formulations. This route isn't just a convenience choice; it reflects a pharmacological advantage specific to CNS-targeting compounds.

The olfactory pathway — the neural route from the nasal mucosa to the brain through the olfactory bulb — provides a pathway that bypasses the blood-brain barrier. Compounds reaching the olfactory epithelium can access brain tissue without needing to cross the BBB through the systemic circulation, allowing CNS concentrations that oral or even subcutaneous administration might not achieve efficiently for molecules of this size and charge.

For Semax specifically, the intranasal route allows peptide access to the hippocampus and frontal cortex — exactly the regions where its BDNF effects have been measured — at doses that would be impractical through other routes.

Subcutaneous injection is used by some practitioners and produces reliable absorption, but the intranasal route is preferred for both compounds specifically because of this brain-targeting advantage.

Honest Evidence Assessment

Semax: Placing this at Promising on the evidence tier framework used throughout this newsletter — one tier above Pinealon. The BDNF mechanism is well-characterized, the preclinical evidence is consistent across multiple laboratories, the Russian clinical data for stroke recovery is the deepest human evidence base for any compound in this category, and the July 2026 FDA advisory committee review signals that Western regulatory evaluation is underway. The gap between "Russian prescription approval" and "Western RCT validation" is real and relevant.

Selank: Also Promising, with a specific upgrade in the anxiety indication where the 62-patient comparative clinical trial gives it more direct human evidence than most peptides can claim. The GABAergic modulation mechanism is well-characterized. The absence of benzodiazepine-type tolerance, sedation, and dependence — if it holds at scale — is a clinically meaningful differentiation. The same Russian-institution concentration caveat applies.

For both: evidence tiers tell you where the science sits, not whether any individual should use them. That judgment involves individual health context, risk tolerance, access to quality-verified product, and ideally a practitioner conversation — particularly given that both compounds affect neurotransmitter systems in ways that can interact with existing medications, particularly GABAergic drugs for Selank.

Regulatory Status

Neither Semax nor Selank is FDA-approved for any therapeutic use in the United States. Both are available in the US as research chemicals under RUO labeling.

Semax is approved as a prescription medication in Russia (Geropharm formulation) for ischemic stroke, cognitive impairment, and optic nerve conditions. Selank is approved as a prescription medication in Russia for generalized anxiety disorder. These Russian formulations are quality-controlled pharmaceutical products — a different situation from gray-market research peptide vials.

Neither Selank nor Semax currently appears on the WADA Prohibited List, but athletes should exercise caution as rules evolve and novel peptides may be added in future updates.

The Bottom Line

Semax and Selank are the most substantiated compounds in the Russian cognitive peptide category — more deeply researched than Pinealon, more directly relevant to cognitive function than BPC-157 or GHK-Cu, and with a regulatory trajectory that suggests Western validation is coming rather than speculative.

They're also specific tools, not general enhancers. Semax addresses cognitive activation, BDNF support, and neuroprotection. Selank addresses anxiety modulation and the cognitive performance that anxiety impairs. Using them interchangeably — or reaching for them without understanding the distinction — misses the point of both.

The provenance caveat remains honest and important: most of what we know comes from Russian research. The independent replication that would settle questions of effect size and long-term safety outside of Russia is still underway. But within those limitations, these are compounds with more scientific depth behind them than most of what occupies the peptide conversation in English-language media.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Semax and Selank are research compounds not approved by the FDA for human therapeutic use in the United States. Both compounds affect neurotransmitter systems — consult a qualified healthcare provider before use, particularly if you take any medications affecting GABA, serotonin, or dopamine systems.